PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial

NCT04814043 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: PD-1 inhibitor

Sponsor

Sun Yat-sen University